Kamada Ltd Stock Price, News & Analysis

Kamada Ltd. (NASDAQ: KMDA) reported total revenues of $103.6 million for fiscal year 2021 and $31.5 million for Q4 2021. For fiscal year 2022, revenues are projected to be between $125 million and $135 million, reflecting a 20% to 30% increase over 2021. EBITDA margins are expected to be 12% to 15%. The company is integrating newly acquired FDA-approved products and expanding U.S. plasma collection operations. A key highlight includes the initiation of GLASSIA royalty payments from Takeda in Q2 2022.

Kamada Ltd. has announced the appointments of Jon R. Knight as Vice President of U.S. Commercial Operations and Jonathan Ward as Director of Facilities and Construction. These changes aim to enhance U.S. operations and expand plasma collection capabilities, especially related to the company’s recently acquired portfolio of four FDA-approved plasma-derived hyperimmune products. Knight's experience in plasma product commercialization and Ward's expertise in facility management are expected to drive sales growth and new center openings, respectively.

Kamada Ltd. (NASDAQ: KMDA) will release its financial results for Q4 and FY 2021 on March 15, 2022. A conference call for investors will follow at 8:30 AM ET, where management will discuss results and answer questions. Kamada is a leader in the plasma-derived biopharmaceutical industry, focusing on expanding its product portfolio, including FDA-approved treatments like GLASSIA® and CYTOGAM®. The company aims to drive growth through robust development and manufacturing capabilities.

Kamada has acquired a portfolio of four FDA-approved plasma-derived hyperimmune products from Saol Therapeutics for $95 million upfront and up to $50 million in sales milestones through 2034. The global revenue from the products is estimated between $40 million to $45 million, with 75% of sales from the U.S. and 20% from Canada. This acquisition positions Kamada to become a global leader in plasma-derived therapies, enhancing its commercial capabilities in the U.S. market while gaining access to eight additional international markets, mainly in the MENA region.

Kamada Ltd. (NASDAQ: KMDA) reported Q3 2021 revenues of $23.0 million, down from $35.3 million in Q3 2020. The company acquired a portfolio of four FDA-approved plasma-derived products from Saol Therapeutics, expected to generate annual revenues of $40 million to $45 million. The transition of GLASSIA® manufacturing to Takeda is complete, moving to a royalty phase in 2022. The company aims to expand its plasma collection capabilities in the U.S. while advancing the Phase 3 InnovAATe trial for Inhaled AAT. As of September 30, 2021, cash and equivalents stood at $99.8 million.

Kamada Ltd. (NASDAQ: KMDA), a plasma-derived biopharmaceutical company, will announce its financial results for the three and nine months ending September 30, 2021, on November 22, 2021. An investment community conference call is scheduled for the same day at 8:30 AM ET, allowing stakeholders to discuss results. Kamada is recognized for its products, GLASSIA and KEDRAB, supported by significant partnerships. The company aims to enhance its growth through commercial products and a robust development pipeline, including treatments for AAT deficiency and COVID-19.

Kamada Ltd. (NASDAQ: KMDA) reported second-quarter 2021 revenues of $24.2 million, down from $33.1 million in Q2 2020. Gross profit decreased to $9.1 million, yielding a gross margin of 37%. The company completed a workforce downsizing, anticipated to reduce annual labor costs by 10%. Net income fell to $0.9 million ($0.02 per share) from $3.5 million ($0.10 per share). Adjusted EBITDA was $2.4 million. Kamada is advancing its Phase 3 InnovAATe trial for inhaled AAT and plans to expand plasma collection centers.

Kamada Ltd. (NASDAQ: KMDA) will release its financial results for Q2 2021 on August 11, before U.S. markets open. A conference call to discuss these results will follow at 8:30 AM ET, available via telephone or a live webcast. The company's leading products include GLASSIA® and KEDRRAB®, with GLASSIA being the first FDA-approved liquid AAT product. Kamada is also advancing clinical trials for inhaled AAT and a hyperimmune IgG product for COVID-19. FIMI Opportunity Fund is the lead shareholder, owning approximately 21% of the company.

Kamada's KEDRAB® has received a significant label update from the FDA, making it the first and only human rabies immune globulin (HRIG) clinically studied in children. This new indication allows for KEDRAB's use in individuals of all ages, crucially addressing the fact that up to 40% of rabies exposures involve children under 15. The label update stems from a successful post-marketing pediatric trial, demonstrating both safety and effectiveness. Kamada anticipates this approval could increase its market share in the estimated $150 million annual U.S. HRIG market.